Ramsay Health Care (ASX: RHC) moves toward November 24 vote on European hospital separation

Ramsay Health Care Limited (ASX: RHC), the Sydney-headquartered private hospital operator with businesses across Australia, the United Kingdom and continental Europe, has progressed the proposed demerger of Ramsay Santé following the registration of its demerger booklet with the Australian Securities and Investments Commission. The 19 October 2026 development follows a Supreme Court of New South Wales order authorising the convening of a shareholder scheme meeting to consider the proposed distribution of Ramsay Health Care’s 52.79% interest in the European hospital company. Ramsay’s directors have unanimously recommended the transaction, while independent expert Deloitte Corporate Finance has concluded that the proposal is in shareholders’ best interests in the absence of a superior alternative. The transaction could materially simplify the group’s reporting and capital structure, but it remains subject to shareholder approvals and the conditions necessary for implementation.

Why is Ramsay Health Care proposing to distribute its 52.79% interest in Ramsay Santé to shareholders?

Ramsay Health Care is seeking to separate its controlling interest in Ramsay Santé from its Australian and United Kingdom hospital businesses. Under the proposed arrangement, shareholders would receive a proportional interest in Ramsay Santé through an in-specie distribution rather than Ramsay selling the entire holding for cash. Existing Ramsay Health Care shares would remain in place, giving participating shareholders an interest in the continuing Australian-listed company alongside the distributed European investment. The arrangement is intended to create two more clearly differentiated investment exposures.

Ramsay Santé operates an extensive European healthcare network covering hospitals, specialist services, mental healthcare and primary care. Its business spans France, Sweden, Norway, Denmark and Italy, giving it a different geographic and regulatory profile from Ramsay Health Care’s Australian and United Kingdom operations. The company is already listed on Euronext Paris and maintains its own management, financing and corporate governance arrangements. These characteristics make a separation operationally different from carving an entirely new business out of a fully integrated corporate division.

The proposed demerger follows a strategic review of Ramsay Health Care’s ownership interest in Ramsay Santé. Management concluded that the businesses have different investment requirements, growth opportunities and capital structures. Separating them could allow each company to pursue its own financial priorities without being assessed exclusively as part of a single consolidated group. The potential benefit depends on whether the resulting companies attract appropriate investor support and deliver improved operating performance.

Ramsay Health Care has indicated that the continuing group would concentrate more directly on its Australian hospital transformation programme and United Kingdom healthcare operations. Ramsay Santé would remain responsible for its European strategy under its existing management framework. The separation could make financial performance easier to evaluate because the Australian company would no longer consolidate the European subsidiary’s results. However, the transaction would not itself increase patient activity or operating margins at either business.

What did the Supreme Court of New South Wales decide about the Ramsay Santé demerger?

On 16 October 2026, Ramsay Health Care announced that the Supreme Court of New South Wales had ordered the convening of a meeting at which shareholders could vote on the proposed scheme of arrangement. The order allows the transaction to advance through the relevant shareholder approval process. It does not constitute final court approval for the demerger or establish that the scheme has become effective. Further legal and procedural requirements remain before implementation.

The company’s board has recommended that shareholders support both the scheme and the associated capital reduction required to implement the distribution. The capital reduction and scheme arrangement involve distinct corporate approvals that are necessary to complete the proposed structure. Ramsay Health Care has scheduled the relevant shareholder meetings for 24 November 2026, immediately after its annual general meeting. The meetings will be held in Sydney, providing shareholders with a formal opportunity to vote on the transaction.

Deloitte Corporate Finance was appointed to assess the proposal independently. The expert concluded that the demerger is in the best interests of Ramsay Health Care shareholders in the absence of a superior proposal. This provides an additional assessment beyond the board’s recommendation, although shareholders must consider the assumptions and qualifications contained in the full report. An independent expert’s conclusion does not eliminate the financial or operational risks associated with the resulting companies.

The demerger booklet contains information about the proposal, shareholder meetings and the independent expert’s assessment. Its registration with ASIC advances the documentation process toward distribution to eligible shareholders. Ramsay previously indicated that dispatch was expected on or before 23 October 2026. The booklet will provide shareholders with details relevant to their voting and potential distribution entitlements.

How would Ramsay Health Care shareholders receive Ramsay Santé shares or ASX-tradeable CDIs?

Ramsay Health Care proposes to distribute its entire 52.79% holding in Ramsay Santé on a proportional basis to eligible shareholders. An in-specie distribution transfers an asset to shareholders rather than paying the equivalent amount entirely in cash. Investors would retain their existing Ramsay Health Care shares while receiving the prescribed Ramsay Santé entitlement if the transaction proceeds. The economic outcome would depend on the respective market values of the two companies following separation.

Ramsay Santé is already traded on Euronext Paris. To facilitate participation by Australian investors, the companies have been pursuing arrangements under which Ramsay Santé interests could also be held through CHESS Depositary Interests traded on the ASX. Such securities would provide exposure to the underlying European-listed shares while using familiar Australian market settlement infrastructure. The arrangements remain subject to applicable approvals and the final terms of the demerger.

The proposal should not be interpreted as creating additional economic value merely by issuing or distributing securities. Before the transaction, Ramsay Health Care owns the majority interest in Ramsay Santé on behalf of its shareholders. After implementation, shareholders would hold their interests through a different corporate structure. Any change in aggregate value would depend on market pricing, transaction costs, operating performance and the strategic benefits or disadvantages of separation.

The distribution may also create different investment preferences among shareholders. Some investors may prefer direct exposure to Australian and United Kingdom healthcare operations, while others may seek the European hospital business’s longer-term recovery or growth prospects. Separate market listings could allow those investors to express their preferences more directly. However, the extent to which the new structure improves liquidity or valuations remains uncertain.

Shareholders will also need to consider the tax consequences described in the demerger documentation. The treatment may differ according to the type of shareholder, residency and applicable tax rules. The transaction should not be assumed to be tax-free for every investor merely because it involves a distribution of shares rather than cash. The final booklet and applicable tax guidance will be important to understanding those consequences.

How could the separation change Ramsay Health Care’s A$18.7 billion consolidated revenue base?

Ramsay Health Care reported approximately A$18.7 billion in consolidated revenue and other income for FY26, reflecting the full consolidation of its Australian, United Kingdom and European operations. The European businesses accounted for approximately A$9.26 billion of underlying segment revenue and other income during the period. Following the demerger, Ramsay Santé would no longer be consolidated into the continuing group’s financial statements if the separation occurs as proposed. This would produce a substantial reduction in reported group revenue even without an equivalent decline in activity at the remaining hospitals.

The company’s Australian operations generated approximately A$6.8 billion in FY26 revenue and other income, while the United Kingdom businesses contributed around A$2.6 billion. These operations would become the principal focus of the continuing Ramsay Health Care group. Their financial performance reflects different funding systems, contractual arrangements and patient demand characteristics from those of continental Europe. The separation could therefore make the underlying performance of the continuing businesses easier to assess.

Ramsay Health Care reported FY26 group EBIT of approximately A$1.105 billion, increasing substantially from the preceding year. Underlying net profit also improved, supported by progress in Australia and operating improvements across the wider group. However, historical consolidated earnings cannot be carried forward unchanged after a significant demerger. The new company perimeter will require investors to reassess revenue, operating margins, financing costs and earnings on the relevant continuing-operations basis.

The distinction between accounting presentation and economic performance is particularly important. Deconsolidating a large subsidiary can produce a dramatic reduction in reported revenue and debt without necessarily changing the value of the underlying businesses by an equivalent amount. Investors must examine which assets, liabilities and earnings remain with each company. Pro forma financial statements and the final transaction documentation will provide a more appropriate foundation for comparison.

Why is Ramsay Santé’s independent debt structure important to the proposed separation?

Ramsay Santé already maintains financing arrangements separate from the main Ramsay Health Care funding group. Its borrowings are not generally funded through the same facilities used by the Australian and United Kingdom operations. This separation can reduce the complexity of the proposed demerger because the European subsidiary is not relying on a completely new debt structure created solely for the transaction. It also means the financial characteristics of the two businesses can be evaluated independently.

Ramsay Santé has undertaken refinancing activity during 2026 to strengthen its financing arrangements ahead of the proposed separation. The company has outlined a strategy focused on operational improvement, capital management and longer-term growth across its European healthcare businesses. Refinancing can provide greater visibility over borrowing terms and maturity requirements. However, the financial return remains sensitive to interest expense, operating cash flow and the performance of hospitals across its markets.

The European business has a different leverage profile from the continuing Ramsay Health Care funding group. This has implications for equity valuation because investors may apply different risk assessments to businesses with different debt burdens and cash generation. Separating the companies could allow each to pursue capital allocation policies more closely aligned with its own operating needs. Nevertheless, the debt obligations remain economic commitments for the respective businesses after separation.

For Ramsay Health Care, the transaction could simplify how creditors and shareholders assess its balance sheet. The continuing group would be more directly exposed to the operating results and financing arrangements of its Australian and United Kingdom businesses. This may make certain financial ratios easier to interpret, but it does not eliminate the remaining capital expenditure and operational requirements. The quality of future cash generation will determine whether the simplified structure creates lasting financial flexibility.

What does the proposed demerger mean for Ramsay Health Care’s Australian hospital transformation?

Ramsay Health Care has identified operational improvement in Australia as a major strategic priority. The FY26 results showed Australian underlying EBIT growth supported by revenue indexation, higher-acuity treatment activity and operating efficiency measures. These developments have strengthened the contribution from the company’s core domestic hospital portfolio. The demerger would place greater emphasis on sustaining those improvements without the financial reporting complexity of the European business.

Private hospitals in Australia operate within a system involving private health insurers, government programmes, medical specialists and patients. Revenue growth depends on treatment volumes, reimbursement arrangements and the mix of procedures performed. Operating costs are influenced heavily by staffing, clinical supplies, property and technology expenditure. The company’s ability to improve profitability depends on balancing these factors without compromising clinical quality.

The Australian division has been investing in service areas where management expects stronger returns, including selected higher-acuity specialties and related clinical infrastructure. Such investments can increase the value of hospital services when patient demand and reimbursement support them. However, they also require capital and clinical workforce capacity. Greater management focus following the demerger may help prioritise these decisions, but it cannot guarantee stronger returns.

Ramsay Health Care’s United Kingdom businesses present a separate operating challenge. The group operates acute hospitals alongside Elysium’s mental healthcare services, creating exposure to National Health Service commissioning and other contractual arrangements. FY26 results showed improvement in underlying EBIT despite mixed revenue conditions. Maintaining that progress will remain important for the continuing group’s earnings after the separation.

What must happen before the Ramsay Santé demerger can complete in December 2026?

The next major milestone is the distribution of the registered demerger booklet and completion of the shareholder voting process. Ramsay Health Care has scheduled its annual general meeting, general meeting and scheme meeting for 24 November 2026. Shareholder approval remains necessary, along with any additional court and regulatory requirements relevant to implementation. The proposed December completion date is therefore indicative rather than unconditional.

The independent expert’s favourable conclusion and unanimous board recommendation support the transaction’s progression, but neither substitutes for the required approvals. Shareholders will need to consider the terms, financial information and expected consequences before voting. The possible availability of Ramsay Santé CDIs on the ASX is another element of the separation process requiring appropriate arrangements. Confirmation of final securities entitlements and the implementation timetable will provide greater certainty.

Ramsay Health Care enters this stage after improving underlying operating performance across its hospital businesses. The demerger could simplify management priorities and allow the European company to pursue its own strategy with a separately identifiable shareholder base. However, the separation is primarily a structural transaction and does not resolve every operating challenge facing either organisation. The next decisive evidence will be shareholder approval, final court and regulatory steps, and successful implementation of the distribution.

If completed, the transaction would leave Ramsay Health Care focused on Australia and the United Kingdom while allowing shareholders to hold a direct interest in Ramsay Santé. Future performance would then be assessed through two different listed investments rather than one consolidated healthcare group. The economic result will depend on the cash generation, balance-sheet strength and operating improvements achieved after separation. Those outcomes will ultimately determine whether the demerger produces the benefits anticipated by the board.

Key takeaways from Ramsay Health Care’s proposed Ramsay Santé demerger

• Ramsay Health Care proposes to distribute its entire 52.79% interest in Ramsay Santé.
• The distribution would take place proportionally through an in-specie scheme arrangement.
• The demerger booklet has advanced through ASIC registration.
• The Supreme Court of New South Wales authorised the convening of a shareholder scheme meeting.
• Ramsay’s directors unanimously recommend the proposal.
• Deloitte Corporate Finance concluded that the demerger is in shareholders’ best interests absent a superior proposal.
• Shareholder meetings are scheduled for 24 November 2026.
• Ramsay Santé is already listed on Euronext Paris, with ASX-tradeable CDI arrangements being pursued.
• The separation would remove Ramsay Santé from the continuing group’s consolidated financial statements.
• Completion is targeted for December 2026, subject to the required approvals.